Yawning and locomotor behavior induced by dopamine receptor agonists in mice and rats.
Dopaminergic (DA) agonist-induced yawning in rats seems to be mediated by DA D3 receptors, and low doses of several DA agonists decrease locomotor activity, an effect attributed to presynaptic D2 receptors. Effects of several DA agonists on yawning and locomotor activity were examined in rats and mice. Yawning was reliably produced in rats, and by the cholinergic agonist, physostigmine, in both the species. However, DA agonists were ineffective in producing yawning in Swiss-Webster or DA D2R and DA D3R knockout or wild-type mice. The drugs significantly decreased locomotor activity in rats at one or two low doses, with activity returning to control levels at higher doses. In mice, the drugs decreased locomotion across a 1000-10 000-fold range of doses, with activity at control levels (U-91356A) or above control levels [(+/-)-7-hydroxy-2-dipropylaminotetralin HBr, quinpirole] at the highest doses. Low doses of agonists decreased locomotion in all mice except the DA D2R knockout mice, but were not antagonized by DA D2R or D3R antagonists (L-741 626, BP 897, or PG01037). Yawning does not provide a selective in-vivo indicator of DA D3R agonist activity in mice. Decreases in mouse locomotor activity by the DA agonists seem to be mediated by D2 DA receptors.
Li
Su-Min
SM
Psychobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, Maryland 21224, USA.
Collins
Gregory T
GT
Paul
Noel M
NM
Grundt
Peter
P
Newman
Amy H
AH
Xu
Ming
M
Grandy
David K
DK
Woods
James H
JH
Katz
Jonathan L
JL
D000704:Analysis of Variance; D000818:Animals; D002800:Cholinesterase Inhibitors / Q000494:pharmacology; D018491:Dopamine Agonists / Q000494:pharmacology*; D018492:Dopamine Antagonists / Q000494:pharmacology; D065127:Dopamine D2 Receptor Antagonists; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D051379:Mice; D008809:Mice, Inbred C3H; D018345:Mice, Knockout; D009043:Motor Activity / Q000187:drug effects* / Q000235:genetics; D010830:Physostigmine / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D017448:Receptors, Dopamine D2 / Q000172:deficiency; D015000:Yawning / Q000187:drug effects* / Q000235:genetics
D002800:Cholinesterase Inhibitors; D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D065127:Dopamine D2 Receptor Antagonists; D017448:Receptors, Dopamine D2; D010830:Physostigmine
Life Sci. 1991;48(26):PL129
1675416
Nature. 1990 Sep 13;347(6289):146-51
1975644
Drug Discov Today. 2005 Jul 1;10(13):917-25
15993811
Pharmacol Biochem Behav. 1995 Oct;52(2):275-80
8577791
Psychopharmacology (Berl). 1998 Jan;135(1):1-16
9489928
J Med Chem. 2005 Feb 10;48(3):839-48
15689168
Neuropharmacology. 1993 May;32(5):509-10
8321432
Psychopharmacology (Berl). 1996 Apr;124(3):231-40
8740044
Psychopharmacology (Berl). 2004 Jul;174(3):341-57
14985929
J Neural Transm (Vienna). 1999;106(11-12):1063-73
10651103
Behav Pharmacol. 1997 Jun;8(2-3):147-59
9833010
Eur J Pharmacol. 1996 Dec 12;317(1):29-38
8982716
J Pharmacol Exp Ther. 2007 Mar;320(3):1216-23
17170311
Neuron. 1997 Jul;19(1):103-13
9247267
Neuropharmacology. 1999 Apr;38(4):555-65
10221759
Neuron. 1997 Oct;19(4):837-48
9354330
Acta Neurobiol Exp (Wars). 1980;40(3):633-42
6969021
J Med Chem. 2005 Jun 2;48(11):3663-79
15916415
Pharmacol Biochem Behav. 1977 Oct;7(4):303-5
200963
Psychopharmacology (Berl). 2007 Aug;193(2):159-70
17393143
Bioorg Med Chem Lett. 2007 Feb 1;17(3):745-9
17095222
Pol J Pharmacol. 2001 Nov-Dec;53(6):571-6
11985330
Neuropharmacology. 1996 Mar;35(3):285-94
8783203
J Pharmacol Exp Ther. 1997 Oct;283(1):7-15
9336302
Neuropharmacology. 1999 Sep;38(9):1389-96
10471093
J Pharmacol Exp Ther. 1995 Dec;275(3):1355-66
8531103
Pharmacol Rev. 1997 Sep;49(3):231-52
9311022
J Pharmacol Exp Ther. 2005 Jul;314(1):310-9
15833897
Neuropsychopharmacology. 2003 Jan;28(1):100-7
12496945